Download PDFPDF
Immunoscintigraphic detection of tumour necrosis factor by radiolabelled certolizumab pegol in patients with erosive hand osteoarthritis: a proof-of-concept study

Footnotes

  • Contributors Study design: RW, PC, BL, GV, FVdB, DE. Data collection: RW, PM, BL. Data analysis: RW. Data interpretation: RW, BL, PC, FVdB, DE. Writing of the report: RW. All authors approved the final version of the manuscript.

  • Funding This work concerns an investigator-initiated study supported by UCB Pharma.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval Ethics Committee of Ghent University Hospital, Belgium.

  • Provenance and peer review Not commissioned; externally peer reviewed.